日前，国家药品监督管理局在其官方网站上宣布，兴齐眼药的0.01%硫酸阿托品滴眼液，简称“低阿”，已正式获得“国药准字”批号，成为我国首例获批上市的用于延缓儿童近视进展的低浓度眼药。这一消息标志着我国在儿童近视防控领域取得了重大突破。
据广州日报全媒体记者梁超仪报道，并得到通讯员邰梦云和唐艳丽的证实，“低阿”滴眼液的上市，为我国广大儿童青少年提供了新的近视防控手段。硫酸阿托品是一种广泛应用于眼科的药物，低浓度的配方旨在有效控制近视加深，同时减少可能的副作用。
然而，专家提醒，虽然“低阿”滴眼液的出现为家长和孩子们带来了希望，但在购买和使用前，务必做好充分的“功课”。家长应咨询专业眼科医生，了解药物的适用人群、使用方法以及可能的副作用，确保在医生的指导下合理使用。此外，防控近视不应仅仅依赖药物，合理用眼、定期检查视力以及户外活动等综合防控措施同样重要。
此次“低阿”滴眼液的上市，不仅丰富了我国的眼科药物市场，也为儿童近视防控提供了更多元化的选择，有望对我国的青少年近视防控工作产生积极影响。
英语如下：
**Historic Breakthrough! First Low-Dose Atropine Eye Drops for Children’s Myopia Control Approved for Sale**
Keywords: Low Atropine launch, myopia drug approval, childhood myopia prevention
**News Content:**
Title: First Low-Concentration Atropine Sulfate Eye Drops Approved for Sale in China, Aiding in Childhood Myopia Control
Recently, the National Medical Products Administration (NMPA) announced on its official website that 0.01% Atropine Sulfate Eye Drops, commonly known as “Low Atropine,” by Xingqi Ophthalmic Medicine, have officially received a “China Drug Approval Number.” This marks the first approval of a low-dose eye medication in the country specifically aimed at slowing the progression of myopia in children. This milestone signifies a significant advancement in China’s efforts to combat childhood myopia.
As reported by Guangzhou Daily’s multimedia journalist, Liang Chaoyi, and confirmed by correspondents Tai Mengyun and Tang Yanli, the launch of the “Low Atropine” eye drops offers a new tool for myopia control among China’s vast population of children and adolescents. Atropine Sulfate is a widely used drug in ophthalmology, and its low concentration formulation is designed to effectively control myopia progression while minimizing potential side effects.
However, experts caution that while the introduction of “Low Atropine” brings hope to parents and children, thorough research should be conducted before purchasing and using the product. Parents are advised to consult with professional ophthalmologists to understand the drug’s target users, application methods, and possible side effects, ensuring its proper use under medical guidance. Moreover, myopia control should not rely solely on medication; balanced eye usage, regular vision checks, and outdoor activities are equally crucial components of a comprehensive prevention strategy.
The approval and market entry of “Low Atropine” not only enrich the country’s ophthalmic drug landscape but also offer more diverse options for childhood myopia control, anticipated to have a positive impact on China’s efforts to address adolescent myopia.
【来源】http://www.chinanews.com/life/2024/04-12/10197360.shtml
Views: 1